News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer
11 August 2022
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01
23 June 2022
OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021
25 March 2022
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
11 March 2022
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board
31 January 2022
OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer
27 January 2022
Events & Presentations
EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018
17 September 2018
54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.
17 July 2018
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017
1 October 2017